Mylan sales and revenue up while EpiPen becomes its first $1 billion-selling product
US generic drugmaker Mylan (Nasdaq: MYL) has reported strong growth throughout the company for the fourth quarter and 2014 full year.
The company reported quarterly total revenue of $2.08 billion, an 18% quarter-on-quarter growth, while full year sales stood at $7.72 billion, up 13% on 2013. The $2.08 billion in revenue, however, missed analysts' prediction of $2.09 billion.
Earnings before interest, tax, depreciation and amortization were up 32% for the quarter, now $682 million, with annual figures at $2.37 billion, up 21% on last year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze